18 Analysts Have This To Say About Crinetics Pharmaceuticals
18 Analysts Have This To Say About Crinetics Pharmaceuticals
18 位分析师对Crinetics Pharmicals有这样的看法
In the last three months, 18 analysts have published ratings on Crinetics Pharmaceuticals (NASDAQ:CRNX), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中，18位分析师公布了对Crinetics Pharmicals（纳斯达克股票代码：CRNX）的评级，提供了从看涨到看跌的不同视角。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表简要概述了分析师最近的评级，提供了对过去30天情绪变化的见解，并与前几个月进行了比较以获得整体视角。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $62.78, a high estimate of $97.00, and a low estimate of $48.00. This upward trend is apparent, with the current average reflecting a 24.89% increase from the previous average price target of $50.27.
分析师分析的12个月目标股价提供了见解，平均目标股价为62.78美元，最高估计为97.00美元，低估值为48.00美元。这种上升趋势显而易见，当前的平均价格较之前的50.27美元的平均目标股价上涨了24.89％。
Breaking...
分...
登录免费看全文
登录/注册